<DOC>
	<DOCNO>NCT01762852</DOCNO>
	<brief_summary>The main clinical study randomize , double-blind , placebo-controlled , long term study involve 100 week treatment period . The purpose study test superiority treatment belimumab 10 mg/kg plus supportive therapy compare placebo plus supportive therapy idiopathic membranous nephropathy ( IMN ) . The purpose study also investigate effect initiate earlier treatment belimumab compare delayed treatment current immunosuppressive treatment regimen . The study also determine pharmacokinetic ( PK ) profile belimumab explore mechanism action Belimumab well effect quality life . All subject ( either active treatment placebo ) receive background supportive therapy throughout main clinical study , include angiotensin-converting enzyme inhibitor ( ACEi ) and/or angiotensin receptor blocker ( ARBs ) unless contraindicate may include statin , diuretic , dietary salt restriction exclude immunosuppressant ( except low dose corticosteroid ) . Screening do within 5 2 week first schedule dose study treatment . A total 94 evaluable subject randomize 1:1 ratio 47 subject receive intravenous belimumab 10 mg/kg 47 receive intravenous placebo . Subjects dose Days 0 , 14 , 28 every 4 week , include , Week 100 , result total 27 dos ( give 104 week drug exposure ) . The dosing frequency adjust every 2 week subject 's proteinuria assess urinary protein creatinine ratio ( PCR ) great 1000mg/mmol ( great 10 g/24 h ) , compensate loss belimumab urine . Subjects withdraw study treatment time study , eg rescue therapy , participate follow-up visit every 12 week week 104 . A subject regard complete main clinical study complete phase main clinical study ( screen , treatment period , 4 week 16 week post last dose short term safety follow-up ) . Subjects complete main clinical study therefore participate main clinical study approximately 28 month . After main clinical study , 5 year ( long term ) follow-up phase ass long term outcome .</brief_summary>
	<brief_title>Efficacy Safety Study Intravenous Belimumab Versus Placebo Subjects With Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Age &amp; Gender : Male female 18 75 year age inclusive , time signing informed consent . Histological diagnosis : Have clinical diagnosis IMN , verify biopsy ( either light microscope immunofluorescence , electron microscope ) last 3 year ( biopsy result [ slide possible ] available independent evaluation ) . For patient relapsed disease , biopsy available within precede 7 year . Proteinuria : Have clinically active disease ( nephrotic range proteinuria ) least 3 month prior screen improvement ( &lt; 30 % reduction ) , despite supportive therapy ( must include maximal tolerated dos ACE inhibitor ARB unless contraindicate , may include statin , diuretic , dietary salt restriction ) . During screen proteinuria must &gt; 400 mg/mmol uPCR ( &gt; 4.0 g per 24 hr ) measure 24 hr urine collection and/or spot urine sample ( early morning possible ) 2 occasion least 7 day apart . Proteinuria patient relapse disease : Patients previously achieve proteinuria &lt; 2 g per 24h least 6 month subsequently relapse proteinuria level document , may eligible provide recurrence within previous 3 year patient know antiPLA2R positive . Female Subject eligible participate pregnant nursing ; nonchildbearing potential . Females childbearing potential must agree use one approve contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimise risk pregnancy point . Female subject must agree use contraception 16 week last dose . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Inclusion Criteria Long Term Followup : Subjects sign informed consent Long Term Followup complete 2 year study treatment 16 week followup visit , withdraw early study treatment complete Week 104 Withdrawn visit . NonIdiopathic MN condition affect kidney : If diagnosis MN secondary condition , subject renal impairment condition MN . Causes secondary MN include ( limited ) Immune disease ( Systemic lupus erythematosus , diabetes mellitus ; rheumatoid arthritis , Hashimoto 's disease , Grave 's disease , mixed connective tissue disease , Sjogren 's syndrome , primary biliary cirrhosis , bullous pemphigoid , small bowel enteropathy syndrome , dermatitis herpetiformis , ankylose spondylitis , graftversushostdisease , GuillainBarre syndrome ) ; Infectious parasitic disease ( Hepatitis B ; Hepatitis C , syphilis , filariasis , hydatid disease , schistosomiasis , malaria , leprosy ) ; Drugs toxin ( Gold , penicillamine , nonsteroidal antiinflammatory agent , mercury , captopril , formaldehyde , hydrocarbon , bucillamine ) ; Miscellaneous ( Tumors exclude reasonable diligence , renal transplantation , sarcoidosis , sickle cell disease , Kimura disease , angiofollicular lymph node hyperplasia ) . AntiPLA2R autoantibody : Patients know negative antiPLA2R autoantibody . Severely reduced deteriorate kidney function : An eGFR screen &lt; 40 mL/min/1.73m^2 ( determined 4 variable version MDRD equation ) kidney function stable ( defined &gt; 15 % decrease eGFR 3 month screen unless due medication change ) . Blood Pressure : Uncontrolled hypertension define blood pressure ( BP ) &gt; 150/90 mmHg ( treatment target &lt; =140/80 ) Prior Therapy : Have receive treatment follow therapy time specified prior Day 0 : Therapy Bcell target therapy except rituximab ( e.g. , anti CD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] , BLySreceptor fusion protein [ BR3 ] , TACI Fc , belimumab ) , Time period : anytime ; Therapy : Rituximab ( subject rituximab treatment 1 2 year prior Day 0 eligible document evidence Bcell repopulation &gt; 50 % pretreatment level ) , Period : 2 year ; Therapy : Abatacept biologic investigational agent B cell target therapy ( i.e . approve sale country use ) , Time Period : 364 day ; Therapy : Cyclophosphamide chlorambucil 3 course systemic corticosteroid concomitant condition ( e.g. , asthma , atopic dermatitis ) . ( Topical inhale steroid permit . ) , Time Period : 180 day ; Therapy : Antitumour necrosis factor ( TNF ) antiIL6 therapy ( e.g . adalimumab , etanercept , infliximab , tocilizumab ) . Interleukin1 receptor antagonist ( e.g . anakinra ) . Other immunosuppressive/immunomodulatory agent ( e.g azathioprine , 6mercaptopurine , mycophenolate mofetil ( PO ) / mycophenolate mofetil hydrochloride ( IV ) , mycophenolate sodium ( PO ) , methotrexate , tacrolimus , sirolimus , thalidomide , leflunomide , mizoribine , ciclosporin ) . Intravenous immunoglobulin ( IVIG ) . Plasmapheresis , leukapheresis , Time Period : 90 day ; Therapy : A nonbiologic investigational agent ( i.e . approve sale country use ) . Intravenous corticosteroid , Adrenocorticotropic hormone ( ACTH ) . Aliskiren . A change dose &gt; 50 % angiotensin pathway antihypertensive ( e.g. , ACE inhibitor , angiotensin receptor blocker ) , Time Period : 60 day ; Therapy : A live vaccine . Greater 30mg/day corticosteroid , Time Period : 30 day ; Therapy : Greater 10mg/day corticosteroid . A change dose corticosteroid . Note : Changes inhale steroid new topical immunosuppressive agent ( e.g. , eye drop , topical cream ) allow , Time Period : 14 day . Transplantation : Have history major organ transplant ( e.g. , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Cancer : Have history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Acute chronic infection : Have require management acute chronic infection currently suppressive therapy chronic infection tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) ; hospitalisation treatment infection within 60 day prior Day 0 ; use parenteral ( IV IM ) antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 60 day prior Day 0 . Liver disease : Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Other diseases/conditions : Have clinical evidence significant unstable uncontrolled acute chronic disease due IMN ( i.e. , cardiovascular , pulmonary , haematologic , gastrointestinal , hepatic , renal , neurological , malignancy infectious disease ) , opinion investigator , could confound result study put subject undue risk ; plan surgical procedure history medical disease ( e.g . cardiopulmonary ) , laboratory abnormality , condition ( e.g. , poor venous access ) , opinion investigator , make subject unsuitable study . Positive serology : Have historically positive HIV test test positive screening HIV . Serologic evidence Hepatitis B ( HB ) infection base result test HBsAg , antiHBc antiHBs . Positive test Hepatitis C antibody confirm sample Hepatitis C RIBA immunoblot assay available . Liver function test : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; =2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Immunodeficiency : Have IgA deficiency ( IgA level &lt; 10 mg/dL ) IgG level &lt; 250 mg/dL previously receive nonglucocorticoid immunosuppression previous 6 month . Laboratory test abnormality : Have clinically significant abnormality screen laboratory assessment ( related disease ) , judge investigator . Drug sensitivity / Anaphylaxis : History sensitivity intolerance study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . Suicidality : Subjects evidence serious suicide risk include history suicidal behaviour last 6 month and/or suicide ideation type 4 5 Columbia SuicideSeverity Rating Scale ( CSSRS ) last 2 month investigator 's judgement , pose significant suicide risk . Substance abuse : Evidence current drug alcohol abuse dependence . Blood donation : Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Benlysta</keyword>
	<keyword>efficacy</keyword>
	<keyword>proteinuria</keyword>
	<keyword>Idiopathic membranous nephropathy</keyword>
	<keyword>GSK1550188</keyword>
	<keyword>anti-phospholipase A2 receptor antibody</keyword>
	<keyword>safety</keyword>
	<keyword>placebo</keyword>
	<keyword>BLyS</keyword>
	<keyword>belimumab</keyword>
	<keyword>Lymphostat-B</keyword>
	<keyword>membrane attack complex</keyword>
</DOC>